NZ594479A - Diagnosis and treatment of gastric-type cancers with siRNA, modified antibodies, or immunotherapy approaches - Google Patents

Diagnosis and treatment of gastric-type cancers with siRNA, modified antibodies, or immunotherapy approaches

Info

Publication number
NZ594479A
NZ594479A NZ594479A NZ59447910A NZ594479A NZ 594479 A NZ594479 A NZ 594479A NZ 594479 A NZ594479 A NZ 594479A NZ 59447910 A NZ59447910 A NZ 59447910A NZ 594479 A NZ594479 A NZ 594479A
Authority
NZ
New Zealand
Prior art keywords
nucleic acid
acid sequence
tumor antigen
gastric
variant
Prior art date
Application number
NZ594479A
Inventor
Ugur Sahin
Ozlem Tureci
Michael Koslowski
Original Assignee
Univ Mainz Johannes Gutenberg
Ganymed Pharmaceuticals Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Mainz Johannes Gutenberg, Ganymed Pharmaceuticals Ag filed Critical Univ Mainz Johannes Gutenberg
Priority to NZ601793A priority Critical patent/NZ601793A/en
Publication of NZ594479A publication Critical patent/NZ594479A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Patent No. 594479 Disclosed is the use of an inhibitor of expression and/or activity of a tumor antigen for the preparation of a pharmaceutical composition for treating or preventing a tumor disease, wherein said tumor antigen comprises an amino acid sequence encoded by a nucleic acid which comprises the nucleic acid sequence according to SEQ ID NO: 1 of the sequence listing or a variant of said nucleic acid sequence, wherein (i) the inhibitor of expression of a tumor antigen is an inhibitory nucleic acid selectively hybridizing to the nucleic acid which comprises the nucleic acid sequence according to SEQ ID NO: I of the sequence listing or a variant of said nucleic acid sequence, or (ii) the inhibitor of activity of a tumor antigen is an antibody specifically binding to said tumor antigen, wherein said variant is a functional variant and said tumor disease is a cancer of the stomach, a gastric cancer, a gastric carcinoma, an adenocarcinoma of the stomach or a metastasis thereof.
NZ594479A 2009-02-20 2010-02-18 Diagnosis and treatment of gastric-type cancers with siRNA, modified antibodies, or immunotherapy approaches NZ594479A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ601793A NZ601793A (en) 2009-02-20 2010-02-18 Methods and compositions for diagnosis and treatment of cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15415909P 2009-02-20 2009-02-20
EP09002458A EP2221063A1 (en) 2009-02-20 2009-02-20 Methods and compositions for diagnosis and treatment of cancer
PCT/EP2010/001035 WO2010094490A1 (en) 2009-02-20 2010-02-18 Methods and compositions for diagnosis and treatment of cancer

Publications (1)

Publication Number Publication Date
NZ594479A true NZ594479A (en) 2013-06-28

Family

ID=40594202

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ594479A NZ594479A (en) 2009-02-20 2010-02-18 Diagnosis and treatment of gastric-type cancers with siRNA, modified antibodies, or immunotherapy approaches
NZ601793A NZ601793A (en) 2009-02-20 2010-02-18 Methods and compositions for diagnosis and treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ601793A NZ601793A (en) 2009-02-20 2010-02-18 Methods and compositions for diagnosis and treatment of cancer

Country Status (14)

Country Link
US (1) US9637548B2 (en)
EP (3) EP2221063A1 (en)
JP (2) JP5809067B2 (en)
KR (1) KR20110128315A (en)
CN (1) CN102325548A (en)
AU (1) AU2010215691B2 (en)
BR (1) BRPI1008566A8 (en)
CA (1) CA2750980A1 (en)
IL (1) IL214255B (en)
MX (2) MX2011008429A (en)
NZ (2) NZ594479A (en)
SG (2) SG173033A1 (en)
WO (1) WO2010094490A1 (en)
ZA (1) ZA201105472B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1762575A1 (en) 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identification of tumor-associated antigens for diagnosis and therapy
EP1970384A1 (en) * 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2166021A1 (en) * 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
KR102340685B1 (en) * 2009-02-20 2021-12-17 가니메드 파마슈티칼스 게엠베하 Methods and compositions for diagnosis and treatment of cancer
AU2015255252B2 (en) * 2009-02-20 2017-11-23 BioNTech SE Methods and compositions for diagnosis and treatment of cancer
PL3305813T3 (en) 2009-11-11 2021-04-19 Astellas Pharma Inc. Antibodies specific for claudin 6 (cldn6)
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
EP2404936A1 (en) 2010-07-06 2012-01-11 Ganymed Pharmaceuticals AG Cancer therapy using CLDN6 target-directed antibodies in vivo
JP6276176B2 (en) 2011-05-13 2018-02-07 ガニメド ファーマシューティカルズ ゲーエムベーハー Antibodies for cancer treatment
BR112014002817A2 (en) * 2011-08-08 2021-09-08 Curelab Oncology Inc Use of a p62 polypeptide, or a nucleic acid encoding p62
CN104114184B (en) 2011-08-10 2017-04-19 兰肯瑙医学研究所 Methods and compositions for the treatment of autoimmune and inflammatory diseases
AU2013292510A1 (en) * 2012-07-19 2015-02-05 Amgen Inc. Human BTNL3 proteins, nucleic acids, and antibodies and uses thereof
KR101329655B1 (en) * 2012-12-13 2013-11-14 강원대학교산학협력단 Massage apparatus using water pressure and control method thereof
EP2964672B1 (en) * 2013-03-05 2019-10-09 Board of Regents, The University of Texas System Specific detection tool for mesenchymal and epithelial-mesenchymal transformed circulating tumor cells
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
GB201312133D0 (en) * 2013-07-05 2013-08-21 Univ Birmingham Immunotherapy
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
TWI777196B (en) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 Novel peptides, cells, and their use against several tumors, methods for production thereof and pharmaceutical composition comprising the same
CN104634907B (en) * 2013-11-11 2018-04-20 上海交通大学医学院附属瑞金医院 Application of amino acid molecular combination as gastric cancer marker
US20210113614A1 (en) * 2018-02-02 2021-04-22 Carsgen Therapeutics Co., Ltd. Combination of cellular immunotherapy
US20230310500A1 (en) * 2020-09-03 2023-10-05 Techno Craft Corporation Ltd. Use of Immune Killer Cell Against Circulating Tumor Cells in Solid Tumor Treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5830755A (en) * 1995-03-27 1998-11-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services T-cell receptors and their use in therapeutic and diagnostic methods
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (en) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine
US5928631A (en) 1997-06-09 1999-07-27 The Procter & Gamble Company Methods for controlling environmental odors on the body using compositions comprising uncomplexed cyclodextrins
US20030166132A1 (en) * 1998-08-26 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU3479700A (en) 1999-02-22 2000-09-14 Incyte Pharmaceuticals, Inc. Genes associated with diseases of the colon
IL151928A0 (en) 2000-03-30 2003-04-10 Whitehead Biomedical Inst Rna sequence-specific mediators of rna interference
EP1992643A3 (en) * 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AT500651B9 (en) 2003-05-27 2010-04-15 Altropus Gmbh ACTIVE IMMUNIZING ANTIBODY
US20080305493A1 (en) 2004-03-08 2008-12-11 Avalon Pharmaceuticals Determining Cancer-Linked Genes and Therapeutic Targets Using Molecular Cytogenetic Methods
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
WO2009126926A2 (en) 2008-04-11 2009-10-15 Bionovo, Inc. Anticancer methods employing extracts of gleditsia sinensis lam
KR102340685B1 (en) * 2009-02-20 2021-12-17 가니메드 파마슈티칼스 게엠베하 Methods and compositions for diagnosis and treatment of cancer
AU2013292510A1 (en) 2012-07-19 2015-02-05 Amgen Inc. Human BTNL3 proteins, nucleic acids, and antibodies and uses thereof

Also Published As

Publication number Publication date
WO2010094490A1 (en) 2010-08-26
JP5809067B2 (en) 2015-11-10
JP2016040253A (en) 2016-03-24
NZ601793A (en) 2013-11-29
IL214255B (en) 2018-05-31
JP2012518608A (en) 2012-08-16
ZA201105472B (en) 2012-10-31
KR20110128315A (en) 2011-11-29
US9637548B2 (en) 2017-05-02
BRPI1008566A2 (en) 2017-06-06
EP2221063A1 (en) 2010-08-25
AU2010215691A1 (en) 2011-08-18
BRPI1008566A8 (en) 2018-01-02
EP3170511A1 (en) 2017-05-24
IL214255A0 (en) 2011-09-27
MX2011008429A (en) 2011-09-29
MX349996B (en) 2017-08-23
SG10201402491YA (en) 2014-07-30
CA2750980A1 (en) 2010-08-26
EP2398497A1 (en) 2011-12-28
SG173033A1 (en) 2011-08-29
US20110318264A1 (en) 2011-12-29
AU2010215691B2 (en) 2015-09-03
CN102325548A (en) 2012-01-18

Similar Documents

Publication Publication Date Title
NZ594479A (en) Diagnosis and treatment of gastric-type cancers with siRNA, modified antibodies, or immunotherapy approaches
RU2013104830A (en) TREATMENT OF CANCER USING ANTIBODIES TARGETED IN VIVO
RU2014108043A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF A MALIGNANT TUMOR
RU2014108045A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF A MALIGNANT TUMOR
RU2014108049A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF A MALIGNANT TUMOR
NZ622452A (en) Lsr antibodies, and uses thereof for treatment of cancer
NZ704295A (en) Compositions and methods for the treatment of infections and tumors
RU2015147287A (en) HUMANIZED ANTIBODIES AGAINST AXL
RU2012137502A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER
RU2012121875A (en) ANTIBODIES RECOGNIZING THE CARBOHYDRATE EPITOP ON CD-43 AND CEA EXPRESSED ON MALIGNANT CELLS, AND METHODS OF APPLICATION
RU2014108042A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF A MALIGNANT TUMOR
RU2013155455A (en) ANTIBODIES FOR THE TREATMENT OF CANCER DISEASES WHICH CLAUDIN IS EXPRESSED 6
RU2014108044A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF A MALIGNANT TUMOR
RU2014138038A (en) PHARMACEUTICAL COMPOSITION FOR TREATING CANCER PREVENTION
EA201390328A1 (en) NEW ANTIGENS-BINDING PROTEINS
NZ594480A (en) Methods and compositions for diagnosis and treatment of cancer
JP2012502938A5 (en)
RU2014138039A (en) PHARMACEUTICAL COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER
JP2010110329A5 (en)
JP2009505676A5 (en)
RU2007136026A (en) OPTIONS IL-21
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
UA99633C2 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
WO2005094348A3 (en) Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer
EP2046836A4 (en) Antibody specifically binding to dr5 and composition for preventing or treating cancers comprising the same

Legal Events

Date Code Title Description
S881 Correction of error according section 88(1) (mistake in register by reason of an error or omission on the part of the patent office)

Free format text: CORRECTION TO APPLICANT (71)

ERR Error or correction

Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER; FILING DATE: 09 AUG 2011; STATUS: REJECTED; TITLE: METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER; FILING DATE: 17 AUG 2012; STATUS: REJECTED; TITLE: METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER; FILING DATE: 28 NOV 2011; STATUS: REJECTED; TITLE: COMPLETE SPECIFICATION NOT ATTACHED TO HARD COPY MAIL; FILING DATE: 12 DEC 2012; STATUS: REJECTED; TITLE: METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF CANCER; FILING DATE: 19 FEB 2013; STATUS: PROPOSED;

Effective date: 20130220

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 18 FEB 2017 BY JAMES + WELLS

Effective date: 20140207

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2018 BY JAMES + WELLS

Effective date: 20170214

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2019 BY JAMES + WELLS

Effective date: 20180216

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2020 BY PAVIS GMBH

Effective date: 20190208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2021 BY PAVIS GMBH

Effective date: 20191231

ASS Change of ownership

Owner name: GANYMED PHARMACEUTICALS GMBH, DE

Effective date: 20201125

Owner name: TRON A TRANSLATIONALE ONKOLOGIE AN DER UNIVE, DE

Effective date: 20201125

ASS Change of ownership

Owner name: BIONTECH AG, DE

Effective date: 20201130

Owner name: TRON A TRANSLATIONALE ONKOLOGIE AN DER UNIVE, DE

Effective date: 20201130

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2022 BY NZ01511P

Effective date: 20210211

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2023 BY PAVIS PAYMENT GMBH

Effective date: 20220208

ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 3680063, TRON A TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITA TSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITA T MAINZ GEMEINNA TZIGE GMBH, FREILIGRATHSTRASSE 12, MAINZ 55131, DE; 3681700, BIONTECH SE, AN DER GOLDGRUBE 12, MAINZ 55131, DE

Effective date: 20220915

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2024 BY ANAQUA SERVICES

Effective date: 20230120

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 18 FEB 2025 BY ANAQUA SERVICES

Effective date: 20240123